Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin
about
The physiological and clinical importance of sodium potassium ATPase in cardiovascular diseasesTarget organ cross talk in cardiorenal syndrome: animal modelsRegulation of renal function and structure by the signaling Na/K-ATPaseThe Trade-Off between Dietary Salt and Cardiovascular Disease; A Role for Na/K-ATPase Signaling?The Role of Na/K-ATPase Signaling in Oxidative Stress Related to Obesity and Cardiovascular DiseaseEffects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathySodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.The Pressure of Aging.Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD.Long-term effects of spironolactone in peritoneal dialysis patientsEndogenous cardiotonic steroids and salt-sensitive hypertension.Ammonium activates ouabain-activated signalling pathway in astrocytes: therapeutic potential of ouabain antagonist.Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.Reactive Oxygen Species Modulation of Na/K-ATPase Regulates Fibrosis and Renal Proximal Tubular Sodium HandlingReduction of Na/K-ATPase potentiates marinobufagenin-induced cardiac dysfunction and myocyte apoptosis.Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists.Elevated Plasma Marinobufagenin, An Endogenous Cardiotonic Steroid, Is Associated With Right Ventricular Dysfunction and Nitrative Stress in Heart Failure.Molecular mechanisms of experimental salt-sensitive hypertension.Attenuation of Na/K-ATPase Mediated Oxidant Amplification with pNaKtide Ameliorates Experimental Uremic Cardiomyopathy.Gender differences in the development of uremic cardiomyopathy following partial nephrectomy: Role of progesterone.Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro-Fibrotic Signaling.Diastolic heart failure in dialysis patients: mechanisms, diagnostic approach, and treatment.Ammonia, like K(+), stimulates the Na(+), K(+), 2 Cl(-) cotransporter NKCC1 and the Na(+),K(+)-ATPase and interacts with endogenous ouabain in astrocytes.Cardiac actions of fibroblast growth factor 23.Protein Interaction and Na/K-ATPase-Mediated Signal Transduction.Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel TargetDuchenne muscular dystrophy fibroblast nodules: a cell-based assay for screening anti-fibrotic agents.Targeting Na/K-ATPase Signaling: A New Approach to Control Oxidative Stress.A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy.Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implications.Na/K-ATPase/src complex mediates regulation of CD40 in renal parenchyma.Telocinobufagin, a Novel Cardiotonic Steroid, Promotes Renal Fibrosis via Na⁺/K⁺-ATPase Profibrotic Signaling PathwaysExogenous Pancreatic Kallikrein Improves Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetes
P2860
Q26764938-92606518-4F94-4CB9-9ACF-301B273C0766Q26851343-0DB7D6E4-FE5A-463F-811B-CA13846CCCA1Q26853429-F30B086A-1D1F-45E2-BC59-F44E9C1B38BDQ26865026-724C22DF-2069-4B00-8446-2BD0E3C7F2A8Q28079023-48C38598-0A92-495A-A422-5923AEE429E6Q28742534-9A5A1FD4-B2CA-4D6F-9659-18A908F98D19Q30235107-75F17169-85BE-4998-BCE4-536F2F278D1FQ30240720-E3C24C01-2C5B-4872-9559-8719D4A8B2E0Q30401905-CCBBFCE7-D1A6-4914-B80D-292FB860795CQ30413119-C50DD0CF-6750-4283-B769-1E31583AB1A7Q34103941-FAD34244-6F7F-4FF4-BE9B-B1DE07D77613Q34391607-3843464F-DF31-4196-8E25-DAB6C495F66AQ35541172-433BCCE7-BFAE-4680-A561-F2D54FE868C7Q35821310-E3F3F023-9FDA-458F-9EDA-F799249F5B27Q35956682-6F1D4D62-E768-4CEB-A991-1CE322E5F069Q35990470-5D46AAA1-020B-4BF2-8A66-40F95C0331E9Q36296874-924310CD-FDF4-4066-9237-64652867245AQ36366178-951A78E5-E411-4A41-B8AC-58186DFB7814Q37307099-41020DAF-0D44-4384-B3B9-25B1EA7D59DFQ37433869-696CE9A1-0B22-4DFE-B0D3-69C3EEBC0AF1Q37434735-D808B114-01EB-44BF-A6A4-2808D0A7FA15Q37978426-F5459BBA-BA8D-4C92-B685-F4912BB76993Q38220273-AEB86D3C-2153-4153-BB7B-453A09DB3322Q38977291-4F370C25-FA96-440F-A14B-C078DDEB9E27Q39371897-8916B4AE-973A-46FA-8255-DEF5977973EBQ42375617-8F039E90-B187-4B10-9B7D-AA950B157CB4Q44110265-A6E6BD80-61A2-4A3B-9ACA-EF2834E373A1Q50108231-AE9394DF-E1AD-4753-8A88-FAF6C4289DD6Q50204724-80DAD22F-C92C-4BF3-B593-CE489AC3C4E6Q51323322-F4469B61-F8C6-4E44-AB1F-74A094B1E7BAQ51768312-C070DF29-6593-460B-8317-F1DACD13C954Q58692613-B3697BD0-C5B1-44B0-851A-409313A6CE1CQ58797121-FD268E8E-68B3-408E-8C5D-2ACAC3F521BC
P2860
Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Spironolactone attenuates expe ...... y antagonizing marinobufagenin
@en
Spironolactone attenuates expe ...... antagonizing marinobufagenin.
@nl
type
label
Spironolactone attenuates expe ...... y antagonizing marinobufagenin
@en
Spironolactone attenuates expe ...... antagonizing marinobufagenin.
@nl
prefLabel
Spironolactone attenuates expe ...... y antagonizing marinobufagenin
@en
Spironolactone attenuates expe ...... antagonizing marinobufagenin.
@nl
P2093
P2860
P1433
P1476
Spironolactone attenuates expe ...... y antagonizing marinobufagenin
@en
P2093
Alexei Y Bagrov
Amjad Shidyak
Christopher J Cooper
Deepak Malhotra
Jiang Tian
Jihad Elkareh
Joseph I Shapiro
Mohamed Taleb
Nasser El-Okdi
Olga V Fedorova
P2860
P304
P356
10.1161/HYPERTENSIONAHA.109.140038
P407
P577
2009-11-02T00:00:00Z